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ABSTRACT
Introduction: Clinical guidelines for the treatment of
hip and knee osteoarthritis recommend non-
pharmacological and non-surgical treatments. Exercise
treatments are recommended as primary strategies,
but speciﬁc exercise programme components have not
been speciﬁed. Early evidence indicates that manual
physiotherapy is effective for hip and knee
osteoarthritis. The Management of Osteoarthritis
(MOA) Trial was designed to evaluate the effectiveness
and cost-effectiveness of physiotherapist-led,
individualised exercise, manual physiotherapy and
a combination of these two interventions in the
treatment of adults with hip or knee osteoarthrits. This
paper describes the methods that will be used to
conduct the economic evaluation of these
interventions within the MOA Trial.
Methods and analysis: This comprehensive
economic evaluation will assess the incremental cost-
effectiveness of physiotherapy plus usual care versus
usual care alone from a societal perspective. The
authors will conduct a cost-consequences analysis
using end-points such as Outcomes Measures in
Rheumatology Clinical TrialsdOsteoarthritis Research
Society International responder criteria and quality-
adjusted life years. The evaluation will have a time
horizon of 1 year (and so discounting will not be
necessary). All costs will be reported in 2009 New
Zealand dollars. The authors will address uncertainty
via bootstrapping to calculate CIs for the mean
incremental cost-effectiveness ratios and by
performing sensitivity analyses.
Ethics and dissemination: Ethical approval was
granted by the Lower South Regional Ethics Committee
of the New Zealand Ministry of Health (ethics reference:
LRS/07/11/044). All participants of the MOA Trial
provided written informed consent for the capture of
their healthcare costs. We will submit the results of the
study for publication irrespective of outcome.
Clinical trials registration
number: ACTRN12608000130369.
ARTICLE SUMMARY
Article focus
- As osteoarthritis of the hip or knee is one of the
most common causes of disability worldwide, the
economic burden to health systems and society is
high.
- There is a need to establish the economic
efﬁciency of conservative interventions recom-
mended as primary treatments for patients with
hip or knee osteoarthritis.
- This protocol paper outlines the methods for
investigating and reporting the cost-effectiveness
of supervised exercise physiotherapy, manual
physiotherapy and a combination of these two
interventions, for treating hip or knee osteoarthritis.
Key messages
- This is the protocol for the economic evaluation
of two interventions within a randomised
controlled trial.
- Economic evaluations within randomised
controlled trials provide decision-makers with
information about an intervention’s efﬁciency.
- The results of this trial and the associated
economic evaluation will allow stake-holders to
make more informed decisions about the optimal
allocation of resources for treating hip or knee
osteoarthritis.
Strengths and limitations of this study
Strengths
- This protocol paper will ensure the methods used
in the economic evaluation are transparent. The
economic evaluation is within a pragmatic trial
design, thereby enhancing external validity and
allowing the intervention’s value for money to be
assessed in a real-world scenario.
Limitations
- We applied a deﬁnition of disease-related health-
care useinanefforttoreducevariability inthecost
estimate, and this precluded the estimation of total
healthcare costs.
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Open Access ProtocolINTRODUCTION
From a public-health viewpoint, hip and knee osteoar-
thritis (OA) are considered to be the most important
musculoskeletal disorders based on their prevalence and
associated disability.
1 2 In New Zealand, 14.8% of adults
are diagnosed as having arthritis,
3 and OA is the sixth
largest burden of disability.
4 Primary total hip and total
knee arthroplasties increased in New Zealand by 14%
and 27% respectively between 2004 and 2008.
5 Public
hospital inpatient costs related to hip and knee OA were
estimated to be $NZ63.8 million in 2005. Direct health-
sector costs for 2005 were 0.39% of GDP, and indirect
costs were estimated to be up to three times
this amount.
6 As New Zealand’s population ages, these
estimates are expected to rise.
7
With the aim of addressing the rising burden of hip
and knee OA, treatment strategies and guidelines
have been developed.
8e11 Although joint-replacement
surgeries are considered to be good value for money,
12 13
they are usually only recommended after more conser-
vative treatments have been exhausted.
81 1Also, owing to
the risk of complications, alternatives to pharmacolog-
ical treatment are sometimes preferred.
14 Non-pharma-
cological, non-surgical treatments such as aerobic and
strengthening exercises are included in current guide-
lines as primary treatments; however, the best means of
delivering these exercises has not been speciﬁed.
81 01 1
Promising, but limited, evidence has emerged for the
effectiveness of other non-pharmacological, non-surgical
treatments such as manual physiotherapy. For patients
with hip OA, manual physiotherapy has been shown to
be superior to a comprehensive exercise programme.
15
For patients with knee OA, the combination of manual
therapy and exercise achieved superior results when
compared with a placebo control
16 and a home exercise
programme.
17
The Management of OsteoArthritis (MOA) Trial was
designed as a 232 factorial randomised controlled trial
investigating the effectiveness and cost-effectiveness
of both a multimodal, individualised, supervised exer-
cise programme and an individualised manual therapy
programme, compared with usual healthcare alone
for the management of pain and disability in adults
with hip or knee OA.
18 The purpose of this paper is
to describe the methods for the economic evaluation
conducted in conjunction with the MOA Trial.
A detailed description of the MOA Trial and
methods for the clinical evaluations are reported
elsewhere.
18
METHODS AND ANALYSIS
Study question
From the viewpoint of (a) society and (b) the New
Zealand health system, is a programme of exercise
therapy or manual physiotherapy, or a combination of
the two, in addition to usual care, cost-effective
compared with usual care alone in the treatment of hip
or knee OA?
Participants
All MOA Trial participants will be included in this anal-
ysis. All participants had OA of the hip or knee as
deﬁned by the American College of Rheumatology
criteria.
19 20 They gave signed, informed consent before
baseline assessments were undertaken.
Description of interventions
The interventions in the MOA Trial are delivered in
addition to usual care. A physiotherapist delivers the
interventions as individualised treatments during nine
1 h clinic visits. The treatments include exercise therapy,
manual physiotherapy and a combination of these two
interventions.
18
Exercise therapy (Ex) consists of a multimodal
programme of warm-up/aerobic, muscle strengthening,
muscle stretching and neuromuscular control exer-
cises.
18 A limited list of additional exercises is available to
treating physiotherapists for exercises to be individu-
alised to patients based on the ﬁndings of physical
examinations.
18
Manual therapy (MT) is deﬁned as the delivery of
manually applied forces through procedures intended to
modify the quality and range of motion of the target
joint and surrounding soft tissues.
18 The primary manual
therapy procedures are prescribed from the intervention
protocol, and a limited list of secondary procedures is
available to treating physiotherapists based on the
physical examination ﬁndings.
Combination therapy (Ex+MT) consists of a combina-
tion of the exercise and manual physiotherapy treat-
ments described above.
The comparator, ‘usual care,’ is deﬁned as the status
quo mixture of interventions for treating hip or knee OA
found in community practice in the metropolitan region
surrounding Dunedin, New Zealand.
21 The beneﬁt of
usual care as a comparator is that it has the potential to
represent the current real-world situation for decision-
makers.
21 The 6-month and 12-month follow-up ques-
tionnaires were designed to capture the use of various
interventions available to participants in community
practice.
Type of economic evaluation
This study is a comprehensive economic evaluation
conducted alongside a randomised controlled trial. It is
a cost-effectiveness analysis that will follow multiple
endpoints (described below), also referred to as a cost-
consequences analysis.
22 The main outcomes will be
healthcare costs related to OA and a general measure of
health-related quality of life (HRQoL) for each inter-
vention compared with usual care, expressed as incre-
mental cost-effectiveness ratios. Clinically relevant
criteria,suchastheOutcomesMeasuresinRheumatology
Clinical TrialsdOsteoarthritis Research Society Interna-
tional (OMERACT-OARSI) responder criteria, have been
suggested for use in economic evaluations of treatments
for OA.
23
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Protocol for economic evaluation of physiotherapy versus usual care for hip or knee OAHealth-related quality of life and quality-adjusted life years
The Medical Outcomes Study-Short Form 12 (SF-12v2)
will be used to assess patient health. This general
HRQoL measure was converted to a six-dimensional
health state classiﬁcation (SF-6D) by Brazier and Roberts
using utility weights from the UK population.
24 The SF-
6D allows for the estimation of a single preference-based
index, the quality-adjusted life year (QALY), which is
recommended as a generic measure of beneﬁt across all
cost-effectiveness analyses.
21 25 A QALY is a year of life
experienced with a particular HRQoL as represented on
a scale from 0 to 1, where 0¼death and 1¼full health. No
negative values indicating health states considered worse
than death are possible using the SF-6D. The mean
QALYs for each group will be estimated, controlling for
baseline utility as recommended by Manca et al.
26
Responder criteria
TheOMERACT-OARSIsetofrespondercriteriaconsiders
both absolute and relative changes in pain or function.
27
An individual is considered a responder to a treatment if
oneoftwocriteriaismet:(1)improvement($50%andan
absolute change is $20%) in pain or function or (2)
improvement ($20% and absolute change $10%) in two
of the following three areas: pain, function and patient’s
global assessment. The MOA Trial captured the pain
domain using the numerical pain-rating scale, the func-
tion domain using the Western Ontario and McMaster
osteoarthritis index, and the patient’s global assessment
using the global rating of change.
18
Perspective
The perspective determines the point of view from which
opportunity costs are deﬁned and measured.
28 The
societal perspective will be used in this study, as it is the
broadest possible and is recommended as the reference
case.
21 29 In addition, we will report direct medical costs
and cost-effectiveness from the perspective of the New
Zealand health system.
Time horizon
We will use a 1-year time horizon for this analysis.
Drummond and colleagues reported that this is a suit-
able time horizon for symptom-modifying interventions
in the treatment of OA.
23 We will also later report
a 2-year time horizon as a secondary analysis, to investi-
gate assumptions regarding the duration of effects.
18
Identiﬁcation of resource use and price weights
The cost of delivering the physiotherapy intervention
will be calculated by identifying the number of times
each participant, randomised to one of the treatment
groups, attended physiotherapy treatment. We will then
calculate the cost of this service by applying the unit cost
of a single treatment visit ($NZ 64.00) to the number of
visits attended. The cost of the home exercise booklets
will also be included in the cost of the treatment groups.
Because questioning the patient directly about trans-
portation costs for clinic visits would have unblinded the
assessor to group allocation (physiotherapy vs usual
care), transportation costs will be calculated by multi-
plying the return distance from the participant’s place of
residence using Google Maps (http://maps.google.
com/), at the University of Otago’s reimbursement rate
of $NZ 0.83 per kilometre.
The Osteoarthritis Cost-and-Consequences Question-
naire was designed to capture healthcare use, co-payments
and out-of-pocket expenses related to hip or knee OA
over the preceding 3-month period.
30 The questionnaire
was developed on the basis of existing tools and recom-
mendations
31e33 with input from experts in public health,
health economics, pharmacy and physiotherapy.
Healthcare services with the potential to contribute
substantially to the cost of OA, such as joint-replacement
surgery, were presented in detail to improve recall.
32 34
The MOA Trial protocol includes administering this
questionnaire at baseline and at 6, 12 and 24 months.
Price weights (unit costs) will be applied to the quantity
of health services reported. Price weights for public
hospital-based inpatient services will be based on New
Zealand’s case-mix framework for publically funded
hospitals for the ﬁscal year 2008/2009: the Weighted
Inlier Equivalent Separations (WIES), with Amendments
for New Zealand from Version 11C to Version WIESNZ,
2008 (WIESNZ08). We will multiply medical and surgical
purchase units of $NZ3983.33 by inpatient service case--
weights to obtain the cost of inpatient services. Emer-
gency visits and specialist visits will be valued according to
the hospital’s volume schedule from its funder. Price
weights for medical imaging will be calculated as
a combination of the relative value unit of the procedure
and the reimbursement amount from the imaging
contract between the hospital and ACC (Accident
Compensation Corporation, New Zealand’s no-fault
insurance scheme for work and non-work injury events).
Private hospital-based services such as joint-replacement
surgery, specialist visits and radiology will be valued at the
amount the hospital charges for these services.
Price weights from the New Zealand Pharmaceutical
Schedule will be applied to the quantity of medications
reported in the questionnaire. This will be done by
extrapolating the daily quantities reported for each
medication out to 3 months and then multiplying the
3-month quantities by the relevant subsidy as reported
in the New Zealand Pharmaceutical Schedule.
35 Over-
the-counter medications will be valued at the average
market price for each medication from an average of at
least three vendors (ie, supermarkets, pharmacies,
health food stores) in the area.
Transportation costs will be captured by participant-
reported taxi or bus charges incurred. Or, if a private car
is used, a cost per kilometre of $NZ0.83 will be applied
to the reported/calculated distance travelled. We will ask
participants to report their mileage; however, if they are
unable to do so, we will ask where they travelled from
and the distance will be calculated via Google Maps
(http://maps.google.com/).
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naire asks participants to report lifestyle adaptations,
aids and adaptations, and the out-of-pocket costs asso-
ciated with any of these changes. For the societal
perspective, we will capture work loss as a result of OA.
When quantifying productivity losses, we will use the
friction-cost method, which only counts productivity loss
for the time it takes to replace a worker.
36 We will apply
a 6-month friction period to a participant’s loss of
productivity during the MOA Trial.
37 In the question-
naire, participants also report their absences from work
during the past month due to OA and the total
work time lost as a result of OA-related interventions
such as total joint replacement. We will apply individual
participant wage rates to lost time.
Because follow-up will be limited to 1 year, discounting
(to recognise the differential timing of costs and bene-
ﬁts) will not be necessary for this economic evaluation.
The quantity of resources used for each cost domain will
be reported separately from the cost. All costs in this
study will be expressed in 2009 New Zealand dollars
($NZ) exclusive of government goods and services tax ;
in 2009 $NZ1 z £0.43.
Study boundaries
This study will include the impact on family members
and friends of helping participants cope with their
OA. Family members’ and friends’ travel costs and
lost productivity from accompanying participants for
OA-related healthcare visits, and any other costs
incurred helping participants (provided the assistance is
OA-related), will be derived from asking participants to
estimate these amounts. Only OA-related costs will be
used for the analysis of the MOA Trial due to the
comorbidities that are abundant in the OA population,
38
and the variance that is likely to be produced within the
cost estimate as a result of including comorbidities.
Participants will be encouraged to deﬁne a GP or
hospital visit as OA-related if it is a follow-up for their hip
or knee complaints, if a signiﬁcant part of the visit is
devoted to their hip or knee complaints, or if the doctor
renews OA-related prescriptions. In addition, visits that
are a result of complications from OA-related manage-
ment will also be captured; for example, visits to
a gastroenterologist because of gastrointestinal
complaints while on non-steroidal anti-inﬂammatory
medications will be counted as ‘OA-related.’
Willingness-to-pay thresholds
Countries such as New Zealand have been observed to
use funding-decision thresholds that are close to twice
the GDP per capita.
39 However, agreed-upon maximum
willingness-to-pay thresholds can vary from one to three
times GDP per capita.
21 40 Hence, one, two and three
times GDP per capita will be used as policy-relevant
willingness-to-pay thresholds in our analyses.
Statistical analysis
The comparison of costs between the physiotherapy
groups and usual care will be carried out using both
univariate and multivariable analysis. The univariate
analysis of cost data will be conducted using one-way
analysis of variance. If our cost data violate the assump-
tions of parametric statistics, non-parametric methods of
analysing group means will be used.
41 Non-parametric
bootstrapping will be used for comparing means and
calculating CIs of cost data that violate parametric
assumptions.
25 42 Multivariable analysis of cost data will
be performed in an attempt to improve the power for
tests of difference between groups by explaining varia-
tion owing to other causes.
25 43 The multivariable anal-
ysis will include baseline costs and effects as covariates in
the model and these prespeciﬁed potential confounding
factors: age, body mass index, baseline pain intensity,
duration since ﬁrst diagnosis, quadriceps muscle
strength, mental health and self-efﬁcacy.
18 A variety of
statistical models can be used for the multivariable
analysis of cost data; each has its strengths and weak-
nesses depending on the distribution of costs in the
study.
43 If no single model appears most appropriate, the
results from a number of different models will be
reported.
43
Missing data will be addressed by a multiple imputa-
tion approach to reﬂect the uncertainty present when
replacing missing data. We will consider censored data if
more than 10% of data are lost to follow-up owing to any
cause other than a participant’s death. We will calculate
the percentage of censored data based on the number of
censored assessments relative to the total number of
potential assessments. If censored data need to be
addressed, the censoring mechanism will be deﬁned
(missing completely at random, missing at random or
missing not at random) and the appropriate statistical
method used.
25 43
Summary measures will be presented along with
sampling uncertainty to describe the best estimate of the
costs and effects of the treatment groups in relation to
the comparator. We will calculate the incremental cost-
effectiveness ratios by dividing the incremental cost by
the incremental health beneﬁt (ie, (CostsPTeCostsUC)/
(EffectsPTeEffectsUC)) for the combined physiotherapy
(PT) groups and usual care (UC), and for each physio-
therapy treatment group, Ex, MTand MT+Ex versus UC.
The incremental differences between these groups
will be reported. CIs will be calculated for the incre-
mental cost-effectiveness ratios, and cost-effectiveness
acceptability curves will be calculated to determine the
likelihood that physiotherapy will be considered cost-
effective using one, two and three times GDP per capita
as policy-relevant willingness-to-pay thresholds.
Sensitivity analysis
Although uncertainty will be addressed through the use
of robust imputation procedures, calculation of CIs and
calculation of cost-effectiveness acceptability curves,
assumptions also need to be considered in sensitivity
analyses. Price weights used in our analyses will combine
weights that are generalisable to the New Zealand
population and others that are peculiar to the Dunedin
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Protocol for economic evaluation of physiotherapy versus usual care for hip or knee OAmetropolitan area. Medical products, appliances and
equipment costs that are peculiar to the Dunedin
metropolitan area will be decreased by 2.5% to 28% to
reﬂect the difference in cost for these services in
different regions in New Zealand based on 2007 and
2010 health-expenditure data from Statistics New
Zealand.
44 The cost of outpatient services, including our
physiotherapy interventions, will be increased by 33.6%
and decreased by 12.3% to reﬂect the difference in
outpatient costs between different regions in New
Zealand.
44
Uncertainty can also arise from the choice of model
for the multivariable analysis of costs.
43 We will develop
several multivariable models to assess this effect on the
cost estimate. If model choice leads to a signiﬁcant
variation in results, multiple models for the analysis of
costs will be presented.
Summary of ﬁndings
Findings will be summarised as pattern 1, 2 or 3 ﬁndings
as presented by Glick et al.
43 Pattern 1 and 2 ﬁndings will
result in a range of values for which a statement of cost-
effectiveness can be made about the intervention with
95% certainty. Pattern 3 ﬁndings will necessitate
a downgrade of the level of conﬁdence with which our
results can be considered (eg, from 95% conﬁdence to
80% conﬁdence). In the event of a pattern 3 ﬁnding, we
will calculate the largest deﬁnable CI that will indicate
the highest level of conﬁdence we can have about the
difference in economic value between the physiotherapy
and usual care groups.
43
Ethics and dissemination
This paper describes the methods for evaluating the cost-
effectiveness of physiotherapy treatments within the
MOA Trial. The HRC and Lottery Grants Board peer-
reviewed the grant application, and the Lower South
Regional Ethics Committee of the New Zealand Ministry
of Health approved the MOA Trial (ethics reference:
LRS/07/11/044).
Data and safety monitoring was initially referred to the
Data and Safety Monitoring Board of the Health
Research Council of New Zealand. The Board consid-
ered the risks low or the recruitment period short, and
referred responsibility back to the MOA Trial Team. We
set up a panel comprising the co-investigators, selected
international advisors, and an independent member to
which the principal investigator reports regularly.
We will submit the results of the trial for publication
irrespective of outcome.
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